NCT03189017View on ClinicalTrials.gov

A Phase I Study of ICP-022 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

July 3, 2017

Primary Completion Date

February 5, 2018

Study Completion Date

October 30, 2018

Conditions
Systemic Lupus ErythematosusRheumatoid Arthritis
Interventions
DRUG

ICP-022

The drug product is a white, round, uncoated tablet.

DRUG

Placebos

The placebo is a white, round, uncoated tablet.

Trial Locations (1)

5000

CMAX Clinical Research, Adelaide

All Listed Sponsors
lead

Innocare Pharma Australia Pty Ltd

INDUSTRY

NCT03189017 - A Phase I Study of ICP-022 in Healthy Subjects | Biotech Hunter | Biotech Hunter